RegenLab USA has filed for IPO. The company makes autologous blood-processing devices (PRP), crosslinked scaffolds, and combination products for regenerative medicine, with 70+ granted patents across

Use of proceeds: sales and marketing, manufacturing equipment for factories in France, Switzerland, and the USA, plus R&D and regulatory spend on clinical studies in Europe and the USA. A vertically integrated buildout, not a pure cash-out. Key risks: dependence on obtaining and maintaining regulatory approvals and clearances, unforeseen challenges in product development and clinical trials, and potential failure to achieve commercial success in target markets. Regenerative medicine lives and dies on the approval... RegenLab runs three manufacturing sites with R&D in the USA, France, and Switzerland, and opened a new Jersey City facility in June 2025, planning roughly 50 hires a year toward ~200 staff. ISO 13485, EU-MDR, and MDSAP certified, with a Konica Minolta Healthcare partnership. Bottom line: a real device maker with global manufacturing and deep IP, riding steady PRP demand. But medtech IPOs have been uneven and PRP claims face regulatory scrutiny. Watch approvals and commercia

Use of proceeds: sales and marketing, manufacturing equipment for factories in France, Switzerland, and the USA, plus R&D and regulatory spend on clinical studies in Europe and the USA. A vertically i